- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
17
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
17 companies
Niagen Bioscience
Market Cap: US$551.8m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$6.89
7D
0.1%
1Y
-10.8%
CytomX Therapeutics
Market Cap: US$715.0m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$4.22
7D
8.8%
1Y
298.1%
Merck
Market Cap: US$259.7b
Operates as a healthcare company worldwide.
MRK
US$104.63
7D
7.0%
1Y
2.9%
Catalyst Pharmaceuticals
Market Cap: US$2.9b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$23.43
7D
0.6%
1Y
6.2%
Incyte
Market Cap: US$20.7b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$105.65
7D
3.5%
1Y
41.6%
Harmony Biosciences Holdings
Market Cap: US$2.0b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$35.56
7D
3.6%
1Y
2.6%
Medpace Holdings
Market Cap: US$17.1b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$606.60
7D
2.5%
1Y
78.1%
ADMA Biologics
Market Cap: US$4.6b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$19.14
7D
11.4%
1Y
-4.8%
Exelixis
Market Cap: US$11.9b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$44.21
7D
4.0%
1Y
21.3%
ACADIA Pharmaceuticals
Market Cap: US$4.2b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$24.81
7D
5.3%
1Y
52.0%
Puma Biotechnology
Market Cap: US$254.5m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.05
7D
3.3%
1Y
49.0%
BioStem Technologies
Market Cap: US$80.9m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$4.83
7D
21.8%
1Y
-65.2%
Rigel Pharmaceuticals
Market Cap: US$925.0m
A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
RIGL
US$50.96
7D
10.3%
1Y
84.6%
Halozyme Therapeutics
Market Cap: US$8.5b
A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
HALO
US$72.66
7D
3.3%
1Y
50.7%
Oramed Pharmaceuticals
Market Cap: US$113.4m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$2.85
7D
10.5%
1Y
20.3%
Eli Lilly
Market Cap: US$988.8b
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
LLY
US$1,104.34
7D
4.2%
1Y
38.8%
Earth Science Tech
Market Cap: US$49.7m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.17
7D
31.1%
1Y
36.0%